LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...

LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com . LEO Pharma Canada is located in Toronto, Ontario.

To learn more about CHE, visit www.TalkCHE.com. LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with ...

No such med has yet been approved in the U.S.—limiting derms to prescribe only general eczema treatments for CHE, which is a distinct condition from eczema—though Leo’s delgocitinib cream, a ...

LEO Pharma and the Parker Institute at Copenhagen University Hospital have entered into a three-year academic partnership aimed at advancing dermatology research. The alliance will focus on enhancing ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

The Pharma CI Europe Conference & Exhibition (April 23-24, 2025) is the industry's gold standard event for senior level pharma, biotech, and medical device professionals who seek the latest in ...